Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.

BMC cancer - 30 Jan 2020

Liu Kejun, Jiang Guanming, Zhang Ailing, Li Zhuanghua, Jia Jun

Abstract excerpt

BACKGROUND: The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is very poor. Currently, therapeutic methods for this patient population include whole-brain radiation therapy (WBRT), surgery, radiosurgery and systemic treatment. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could be effective on cerebral metastases of mutated NSCLC. However, which EGFR-TKIs is more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Protein Kinase Inhibitors
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Gefitinib

Share to Kaplan-Meier Estimate

Share to Molecular Targeted Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 32000711
DOI: 10.1186/s12885-020-6543-y
PMCID: PMC6993327

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.PMID 32000711Read ↗

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancerSemantic proximity Read ↗

Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.Semantic proximity Read ↗

Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.Semantic proximity Read ↗

Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.Semantic proximity Read ↗

Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.Semantic proximity Read ↗

Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.Semantic proximity Read ↗

Combined BBB-penetrant tyrosine kinase inhibitor and intracranial radiotherapy versus BBB-penetrant tyrosine kinase inhibitor alone for the treatment of EGFR-mutated non-small cell lung cancer patients with brain metastasesSemantic proximity Read ↗

Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.Semantic proximity Read ↗

Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.Semantic proximity Read ↗

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.Semantic proximity Read ↗

Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer.Semantic proximity Read ↗

[Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated Non-small Cell Lung Cancer and Brain Metastases].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.